Edition:
India

People: Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

9.82USD
19 Jul 2019
Change (% chg)

$-0.29 (-2.87%)
Prev Close
$10.11
Open
$10.13
Day's High
$10.13
Day's Low
$9.78
Volume
285,223
Avg. Vol
296,204
52-wk High
$20.85
52-wk Low
$9.51

Carter, Paul 

Mr. Paul Rutherford Carter is Independent Director of the Company. Mr. Carter has served as a member of our Board of Directors since September 2015. From April 2006 to August 2016, Mr. Carter served in various roles at Gilead Sciences, Inc., a research based biopharmaceutical company, most recently serving as Executive Vice President, Commercial Operations. Prior to joining Gilead, Mr. Carter spent 15 years in the pharmaceutical industry with GlaxoSmithKline and its legacy companies. During his time with GlaxoSmithKline, Mr. Carter gained increasing levels of senior experience as General Manager in Europe and later as a Regional Head of the International Business in Asia. Mr. Carter currently serves on the board of directors of Hutchison China Meditech Ltd, a biopharmaceutical company. Mr. Carter holds a degree in Business Studies from the Ealing School of Business and Management (now merged into University of West London) and is a Fellow of the United Kingdom’s Chartered Institute of Management Accountants.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 215,590
Fiscal Year Total, USD 215,590

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Robert Azelby

10,130,800

Carlos Campoy

1,844,370

Erin Lavelle

3,680,390

James Bucher

1,961,540

Randal Hassler

4,217,190

Nadia Dac

--
As Of  31 Dec 2018